Fougera Pharmaceuticals
As of the edition of 20 October 2026, Fougera Pharmaceuticals runs 12 drugs, 11 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Stopped | 1 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Diclofenac | none listed | 7 |
| Fluticasone propionate | none listed | 2 |
| Fluticasone | none listed | 2 |
| Betamethasone | none listed | 6 |
| Betamethasone dipropionate | none listed | 3 |
| Clobetasol propionate | none listed | 2 |
| Betamethasone valerate | none listed | 4 |
| Alclometasone dipropionate | none listed | 0 |
| Oxiconazole | none listed | 0 |
| Terconazole | none listed | 0 |
| Methscopolamine | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Immune system: 4 trials led
- Inherited and neonatal: 4 trials led
- Skin and connective tissue: 4 trials led